Search Results

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that the company will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th, 2024.

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.

Renexxion LLC announced that the company will present at the Oppenheimer Healthcare Private Company Showcase on Wednesday, October 11th, 2023.

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, announced today that the United States Patent Office (“USPTO”) has issued a new composition of matter patent (Patent no. 11,643,409) and a method of use patent (Patent no. 11,827,631), both covering a novel crystal isoform of naronapride.

Renexxion Ireland Limited (“Renexxion”) announced today that it has completed a successful pre-Investigational New Drug (pre-IND) consultation with the U.S. Food and Drug Administration (U.S. FDA) to discuss development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD).

Renexxion Ireland Limited announces U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application of naronapride for the treatment of patients with proton-pump inhibitor (PPI) non-responsive symptomatic gastroesophageal reflux disease.

Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.

Renexxion Ireland Limited (Renexxion) is pleased to announce opening of the Investigational New Drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with cystic fibrosis (CF), a first step towards conducting clinical trials of this drug candidate in CF patients.